Hengrui Pharmaceuticals' Innovative Pipeline Seen as Undervalued -- Market Talk

Dow Jones04-23

1019 GMT - Hengrui Pharmaceuticals' diversified innovative pipeline is undervalued, Citi analysts say in a note. The drugmaker's innovative drug sales rose 26% on year in 1Q, and innovative products accounted for a larger proportion of total sales. Management said hospital access accelerated in March, which Citi views as a solid foundation for sales growth in 2026, while new product approvals this year could provide additional upside. Coming clinical data readouts should also drive a re-rating, it adds. Citi maintains its buy rating, with target prices of 123.00 yuan for A shares and HK$134.00 for H shares. The bank also names Hengrui as its top pick in China's pharmaceutical sector. A shares closed at 56.40 yuan, while H shares ended at HK$68.70. (jason.chau@wsj.com)

(END) Dow Jones Newswires

April 23, 2026 06:19 ET (10:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629022887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629022887","market":"hk","top_or_hot":-1,"title":"Hengrui Pharmaceuticals' Innovative Pipeline Seen as Undervalued -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1019 GMT - Hengrui Pharmaceuticals' diversified innovative pipeline is undervalued, Citi analysts say in a note. The drugmaker's innovative drug sales rose 26% on year in 1Q, and innovative products accounted for a larger proportion of total sales. Management said hospital access accelerated in March, which Citi views as a solid foundation for sales growth in 2026, while new product approvals this year could provide additional upside. Coming clinical data readouts should also drive a re-rating, it adds. Citi maintains its buy rating, with target prices of 123.00 yuan for A shares and HK$134.00 for H shares. The bank also names Hengrui as its top pick in China's pharmaceutical sector. A shares closed at 56.40 yuan, while H shares ended at HK$68.70. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2026 06:19 ET (10:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharmaceuticals' Innovative Pipeline Seen as Undervalued -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharmaceuticals' Innovative Pipeline Seen as Undervalued -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-23 18:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1019 GMT - Hengrui Pharmaceuticals' diversified innovative pipeline is undervalued, Citi analysts say in a note. The drugmaker's innovative drug sales rose 26% on year in 1Q, and innovative products accounted for a larger proportion of total sales. Management said hospital access accelerated in March, which Citi views as a solid foundation for sales growth in 2026, while new product approvals this year could provide additional upside. Coming clinical data readouts should also drive a re-rating, it adds. Citi maintains its buy rating, with target prices of 123.00 yuan for A shares and HK$134.00 for H shares. The bank also names Hengrui as its top pick in China's pharmaceutical sector. A shares closed at 56.40 yuan, while H shares ended at HK$68.70. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2026 06:19 ET (10:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2495084118.USD","symbol_name":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629022887","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629022887","pubTimestamp":1776939540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1019 GMT - Hengrui Pharmaceuticals' diversified innovative pipeline is undervalued, Citi analysts say in a note. The drugmaker's innovative drug sales rose 26% on year in 1Q, and innovative products accounted for a larger proportion of total sales. Management said hospital access accelerated in March, which Citi views as a solid foundation for sales growth in 2026, while new product approvals this year could provide additional upside. Coming clinical data readouts should also drive a re-rating, it adds. Citi maintains its buy rating, with target prices of 123.00 yuan for A shares and HK$134.00 for H shares. The bank also names Hengrui as its top pick in China's pharmaceutical sector. A shares closed at 56.40 yuan, while H shares ended at HK$68.70. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0060":"抗癌","BK0028":"国家队","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0196":"行业龙头","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0239":"医药制造","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0183":"MSCI概念","BK0188":"融资融券","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0012":"证金概念","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC"},"translate_title":"恒瑞医药的创新管线被认为被低估——市场谈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9},"content_text":"1019 GMT - Hengrui Pharmaceuticals' diversified innovative pipeline is undervalued, Citi analysts say in a note. The drugmaker's innovative drug sales rose 26% on year in 1Q, and innovative products accounted for a larger proportion of total sales. Management said hospital access accelerated in March, which Citi views as a solid foundation for sales growth in 2026, while new product approvals this year could provide additional upside. Coming clinical data readouts should also drive a re-rating, it adds. Citi maintains its buy rating, with target prices of 123.00 yuan for A shares and HK$134.00 for H shares. The bank also names Hengrui as its top pick in China's pharmaceutical sector. A shares closed at 56.40 yuan, while H shares ended at HK$68.70. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 06:19 ET (10:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629022887","isCrawlerRequest":true}